123 completed, 31 terminated, 13 unknown, 11 recruiting. 200 Phase 2, 38 Phase 1, 7 Phase 3.
Follow Topotecan: new trials by email Literature Review of Topotecan trials Research Report on Topotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Eflornithine, Topotecan, Cyclophosphamide - Osteosarcoma, Ewing Sarcoma | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 406 | 2026-06-05 | 2026-10-06 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer Organoid Drug Sensitivity Testing-Guided Therapy, Topotecan - Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC) | Phase 2 / Phase 3 | Not yet recruiting | Peking Union Medical College Hospital | 128 | 2025-08-01 | 2025-08-06 |
| A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer IBB0979, topotecan hydrochloride for injection - Small Cell Lung Cancer | Phase 2 | Not yet recruiting | SUNHO（China）BioPharmaceutical CO., Ltd. | 200 | 2025-08-01 | 2025-07-21 |
| Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment Intravitreal topotecan, Retinal detachment surgery - Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy | Phase 2 | Not yet recruiting | Unity Health Toronto | 394 | 2025-03-01 | 2025-03-06 |
| Oral Topotecan With Toripalimab for Patients With Endometrial Cancer Topotecan, Toripalimab - Endometrial Cancer | Phase 2 | Not yet recruiting | Fudan University | 30 | 2024-11-30 | 2024-08-12 |
| A Multi-Arm, Platform Trial For Relapsed Neuroblastoma Bevacizumab, Dinutuximab beta, Irinotecan (drug) - Relapsed Neuroblastoma | Phase 1 / Phase 2 | Recruiting | University of Birmingham | 160 | 2024-11-11 | 2026-01-12 |
| Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide - Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer | Phase 2 | Active not recruiting | BioNTech SE | 110 | 2024-08-05 | 2026-09-14 |
| N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma DANYELZA, Sargramostim, Cytoxan - High-risk Neuroblastoma, Neuroblastoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 45 | 2024-07-22 | 2026-08-28 |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer R-DXd, Paclitaxel, Topotecan - Solid Cancer | Phase 2 / Phase 3 | Recruiting | Daiichi Sankyo | 860 | 2024-02-27 | 2026-10-26 |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) Peluntamig (PT217), Carboplatin + Etoposide, Paclitaxel. - Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC) | Phase 1 / Phase 2 | Recruiting | Phanes Therapeutics | 203 | 2023-09-05 | 2026-07-15 |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
| Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer Carboplatin, Pemetrexed, Paclitaxel - Lung Cancer, Small-cell Lung Cancer | Phase 2 | Recruiting | Fox Chase Cancer Center | 280 | 2023-02-22 | 2026-05-22 |
| A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD) - Neoplasms, Ovarian | Phase 2 | Terminated | Bristol-Myers Squibb | 106 | 2023-02-01 | 2026-10-28 |
| Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma Surgical resection, Ommaya/VPS, Methotrexate - Medulloblastoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 130 | 2022-12-20 | 2026-09-15 |
| Rapid Administration Pilot for Infusing Dinutuximab Dinutuximab with Chemotherapy - Neuroblastoma | Phase 2 | Active not recruiting | Children's Hospital Los Angeles | 30 | 2022-11-29 | 2026-09-17 |
| Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma Anti Thymocyte Globulin, Fludarabine, Cyclophosphamide injection - Neuroblastoma | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 64 | 2022-08-01 | 2022-07-01 |
| Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2022-06-30 | 2023-09-26 | |
| A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Seclidemstat - Ewing Sarcoma, Myxoid Liposarcoma | Phase 1 / Phase 2 | Unknown | Salarius Pharmaceuticals, LLC | 10 | 2022-01-15 | 2023-08-01 |
Showing 20 of 200. Sign in to see all of them.
Ovarian Neoplasms (43) · Small Cell Lung Carcinoma (37) · Lung Neoplasms (24) · Carcinoma, Ovarian Epithelial (23) · Neuroblastoma (21) · Fallopian Tube Neoplasms (18) · Uterine Cervical Neoplasms (12) · Brain Neoplasms (11) · Leukemia (11) · Leukemia, Myeloid, Acute (9) · Neoplasms (9) · Sarcoma (8) · Central Nervous System Neoplasms (7) · Recurrence (6) · Anemia, Refractory, with Excess of Blasts (5)
National Cancer Institute (NCI) (24) · St. Jude Children's Research Hospital (10) · Alliance for Clinical Trials in Oncology (9) · GlaxoSmithKline (8) · SCRI Development Innovations, LLC (7) · Gynecologic Oncology Group (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · Fox Chase Cancer Center (4) · M.D. Anderson Cancer Center (4) · Memorial Sloan Kettering Cancer Center (4) · Case Comprehensive Cancer Center (3) · Children's Oncology Group (3) · Gustave Roussy, Cancer Campus, Grand Paris (3) · Mayo Clinic (3) · ARCAGY/ GINECO GROUP (2)
United States (143) · Canada (29) · France (17) · Spain (14) · United Kingdom (14) · Australia (13) · South Korea (13) · Italy (11) · Germany (9) · Belgium (8) · Poland (7) · Puerto Rico (7) · China (5) · Japan (5) · Netherlands (5)
Anthony Greco, MD (4) · James R. Jett, MD (3) · Amar Gajjar, MD (2) · Amy D. Tiersten, MD (2) · Anish Thomas, M.D. (2) · Antonius A. Miller, MD (2) · Carlos Rodriguez-Galindo, MD (2) · David R. Spigel, MD (2) · David S. Miller, MD (2) · Jung-min Lee (2) · Karen K. Fields, MD (2) · Russell J. Schilder, MD (2) · Wayne L Furman, MD (2) · Aditi Bagchi, MD, PhD (1)
PMID 42820295, PMID 14534883, PMID 14586216, PMID 14766258, PMID 14970858, PMID 15145163, PMID 15975641, PMID 16158312, PMID 16382125, PMID 16435380, PMID 16755177, PMID 16966261, PMID 17336213, PMID 17409859, PMID 17409984, PMID 17607121, PMID 18447671, PMID 18538834, PMID 18621625, PMID 18977518, PMID 19307014, PMID 19427025, PMID 19726073, PMID 19804455, PMID 19935387, PMID 20521352, PMID 21168198, PMID 21620511, PMID 21663862, PMID 21815133, PMID 23391616, PMID 23591400, PMID 24172094, PMID 24563078, PMID 25002722, PMID 25490004, PMID 26200278, PMID 26755507, PMID 27597276, PMID 27694157, PMID 29252124, PMID 29778738, PMID 30104007, PMID 30537991, PMID 31401903, PMID 31538815, PMID 31595663, PMID 31831561, PMID 32221013, PMID 32994466
U10CA180868 (5), U10CA031946 (4), U10CA180886 (3), 2009 (2), 2016 (2), 2018 (2), U10CA021115 (2), U10CA027469 (2), U10CA098543 (2), 2004 (1), 2008 (1), 2015 (1), N01CM00070 (1), N01CM00099 (1), N01CM00100 (1)